NCT07237100 2025-11-19
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Sutter Health
Phase 2 Recruiting
Clinical Trials
5 trialsNCT03962543 2025-08-07
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT06159166 2025-04-23
Mirda
Johns Hopkins University
Phase 1/2 Recruiting
NCT05028166 2024-03-15
Individual Patient Compassionate Use of Mirdametinib
SpringWorks Therapeutics, Inc.
Available
NCT02096471 2019-01-10
MEK Inhibitor
University of Alabama at Birmingham
Phase 2 Completed